Common side effects and treatment methods of brigatinib/brigatinib (Embry)

Brigatinib (Brigatinib), as a highly effective ALK inhibitor, has significant advantages in the efficacy of non-small cell lung cancer, but it is also accompanied by a series of side effects, some of which are related to its molecular mechanism. The most common side effects include gastrointestinal discomfort (such as nausea, diarrhea), musculoskeletal symptoms (such as myalgia, arthralgia), skin reactions (such as rash), and laboratory abnormalities (such as elevated serum enzymes). The frequency and severity of these side effects vary between individuals, but most can be improved in clinical practice through dose adjustment, supportive care, and symptomatic treatment.

One of the more special side effects is the early pneumonia-like reaction of brigatinib. Generally, cough, dyspnea or hypoxemia may occur within the first week of taking the drug. Overseas research suggests that although the incidence of this phenomenon is not high, it requires doctors to be highly vigilant. Once relevant symptoms occur, medications should be discontinued in a timely manner and imaging examinations and supportive treatments should be performed. For most patients, this adverse reaction can be controlled with gradual dose adjustment.

In terms of management strategies, mild to moderate adverse reactions can be alleviated with short-term medication, such as using antidiarrheal drugs to control diarrhea or using topical preparations to improve skin symptoms. For elevated serum enzymes or abnormal laboratory indicators, doctors usually monitor hematology and liver and kidney function indicators to evaluate whether treatment needs to be reduced or suspended. If the side effects reach a serious level, it is usually recommended to temporarily discontinue the drug and then restart at a lower dose after the symptoms are relieved to ensure a balance between efficacy and safety.

Additionally, patient education is equally important in side effect management. Letting patients know about possible early symptoms and provide timely feedback can significantly reduce the risk of serious adverse events. The clinical team will also conduct close follow-up before and after medication to ensure that any side effects can be identified and intervened in time.

Reference materials:https://www.alunbrig.com/